Universal CAR T Cells Treat Leukemia

Area of Science:

• Immunology
• Oncology
• Pediatrics

Background:

• Relapsed, refractory B-cell acute lymphoblastic leukemia (B-ALL) in infants presents significant treatment challenges.
• Existing CAR T-cell therapies often require patient-specific T-cell collection and manufacturing, leading to delays and logistical hurdles.

Purpose of the Study:

• To evaluate the safety and efficacy of a universal, donor-derived CD19-targeting chimeric antigen receptor (CAR) T-cell therapy in infants with relapsed, refractory B-ALL.
• To establish the feasibility of utilizing allogeneic CAR T-cells for pediatric leukemia treatment.

Main Methods:

• Treatment of two infants with relapsed, refractory B-ALL using CD19-targeting CAR T-cells sourced from an unrelated donor.
• Monitoring for treatment response, remission status, and adverse events.

Main Results:

• Both infants achieved complete remission following the CAR T-cell therapy.
• The therapy was safely administered, with no major adverse events reported related to the allogeneic CAR T-cells.

Conclusions:

• Universal, donor-derived CAR T-cell therapy is a safe and effective treatment option for infants with relapsed, refractory B-ALL.
• This approach overcomes the manufacturing and logistical challenges associated with autologous CAR T-cells, potentially expanding access to this life-saving therapy.